The ad is persuasive because it’s partly true. Sixty markers, one blood draw, no appointment, a price printed right on the page. No one asks why you want it. No one tells you to come back in six months.
Two weeks later you log in to a dashboard. Eleven of your sixty markers glow yellow or red. Below each one sits a short paragraph explaining what that number “may indicate,” and below that, conveniently, a product that addresses it.
You now have a decision to make, and you’re making it with less context than a clinician would have and more urgency than the numbers deserve.
Ordering your own lab work is legal in much of the country, genuinely useful in some situations, and structured in a way that almost nobody explains to the person paying. This is how it works.
How these services are put together
Direct access testing is the technical name. A CLIA explainer posted on the Centers for Medicare & Medicaid Services website, versioned March 2019, defines it as testing “generally defined as consumer (as opposed to physician) initiated testing of human specimens.” You’ll also see it called patient-authorized testing.
The mechanics are simple from your side. You pay online. You get a requisition. You go to a draw site, or a collection kit arrives in the mail. A laboratory runs the samples. Results post to a portal, usually with the company’s own commentary layered on top.
The part worth understanding is the signature on that requisition.
Under CLIA, laboratories performing anything above the simplest tier need a written or electronic request from what the regulations call an authorized person. Federal regulation defines that as someone authorized under state law to order tests, or to receive results, or both. That requirement is the reason a physician’s name typically shows up on a consumer lab order. The company contracts with a clinician or a physician network, and that clinician signs off on orders from people they will never meet, never examine and never follow up with.
That isn’t necessarily sinister. It’s plumbing. But it means the word “physician-ordered” on a marketing page is describing a signature, not a relationship. Nobody in that chain is responsible for what happens to you next.
Results, under the same federal rules, go to authorized persons and to patients who request them through the laboratory’s identity verification process. That last provision is why you can get your own numbers at all.
CLIA governs the lab, not who ordered the test
This distinction is the one that resolves most of the confusion.
The Clinical Laboratory Improvement Amendments, passed by Congress in 1988, set the quality rules for laboratories testing human samples in the United States. Three federal agencies split the work. According to the FDA, CMS issues laboratory certificates, runs inspections, enforces compliance and approves proficiency testing programs. The FDA categorizes tests by complexity and reviews waiver applications. The CDC develops technical standards and laboratory practice guidelines and runs the advisory committee. CMS describes the logic simply: the harder the test, the stricter the requirements. The program covers roughly 320,000 laboratory entities.
Two things follow from this, and they pull in opposite directions.
The reassuring one: CLIA does not care who ordered your test. The CMS explainer is explicit that direct access testing is not treated differently from provider-ordered testing. A lab running a consumer-ordered panel needs the same certificate and meets the same requirements as one running a hospital’s work. The analytical floor is the same.
The less reassuring one: CLIA regulates laboratories, not ordering. The CMS document says plainly that state laboratory laws are what govern who may order a test and receive a result, and that those laws can limit the availability of direct access testing. Some states prohibit it outright. Others allow it for some tests and not others. The rules vary enough state to state that any specific claim about where you can and cannot order your own blood work needs checking against your own state’s laboratory statute, not against a company’s shipping map.
There’s a third framework people conflate with both. The FDA’s page on direct-to-consumer tests explains that tests sold for non-medical purposes, general wellness, or low-risk medical uses are generally not reviewed by the agency before sale, while tests for moderate- to high-risk medical purposes generally are. So “performed in a CLIA-certified laboratory” and “FDA reviewed this test” are separate claims. The first says the lab follows quality rules. It says nothing about whether the test predicts anything useful.
A date note: that FDA page carries content dated December 20, 2019. It states that as of then, the agency had not authorized any direct-to-consumer pharmacogenetic test claiming to predict how you’ll respond to a specific drug. That’s a point that could have changed, so verify the current page before relying on it.
What direct access testing genuinely gives you
Skepticism isn’t the same as dismissal, and there are real reasons people buy these panels.
Access without a gatekeeper. If getting a basic blood draw through your plan means a visit to get the order, a second visit for the draw and three weeks of phone tag, paying cash for the same test in four days is a rational choice. Not everyone has a primary care clinician. Not everyone can take two mornings off.
A price you can see before you buy. Posted prices are rare in American health care. You can compare a consumer panel’s cost against a hospital’s chargemaster or your deductible and know what you’re spending. That’s not nothing.
Data for people who were waved off. Some people order their own labs because they described symptoms and were told it was stress, or weight, or anxiety, and nobody ran anything. Walking into the next visit with results in hand changes the conversation. That’s a legitimate use, and dismissing it would be dishonest.
Tracking something you already know about. If you and your clinician have agreed to watch a value between visits, a cash test can fill the gap.
Privacy. Some people want a result that doesn’t start in a chart. Whether the testing company protects that data better than a clinic does is a separate and complicated question, and health privacy law treats these companies very differently from providers.
Two ways a big panel misleads you
Run enough tests and something will flag
MedlinePlus explains that a reference range is built from the results of large groups of healthy people, and that healthy people sometimes land outside it. The site also says, straightforwardly, that the word “normal” can be misleading.
Sit with the consequence. If a range is drawn so that most healthy people fall inside it, then by construction some healthy people fall outside it on any given test. One test, small chance of a stray flag. Forty tests, forty chances. A long panel run on a perfectly healthy person will very likely produce at least one colored bar, and that bar is arithmetic, not illness.
Nothing on the dashboard tells you this. Each marker is presented as if it were the only test you ran.
The follow-up is where the cost lands. Clare Fiala, Jennifer Taher and Eleftherios Diamandis, writing in Clinical Chemistry and Laboratory Medicine in 2019, examined large-scale wellness testing projects that ran extensive labs on healthy volunteers. They raised over-diagnosis, over-treatment and incidental findings as real harms, and questioned the underlying premise that “improving” a biomarker number is itself a health goal.
The broader evidence is sobering. A 2019 Cochrane systematic review by Lasse Krogsbøll and colleagues pooled 17 randomized trials of general health checks in adults. The 15 trials that reported outcome data covered nearly 252,000 participants. Health checks had little or no effect on total mortality, with a risk ratio of 1.00 across 11 trials and more than 233,000 participants, rated high-certainty evidence. The same went for cancer deaths. The authors’ conclusion was that general health checks are unlikely to be beneficial.
Be careful with that finding. Those trials studied organized screening programs inside health systems, not commercial online panels, so it isn’t a direct test of what these companies sell. But it’s the largest body of evidence we have on the idea underneath them: that testing broadly in people without symptoms makes them healthier. It mostly didn’t.
The reverse error is real too. MedlinePlus notes that a result inside the range doesn’t guarantee good health, and some people with real problems test normal. A clean panel isn’t a clean bill of health.
“Optimal” is a marketing word, not a lab word
The reference range printed on your report belongs to the lab that ran the test. MedlinePlus is clear that laboratories using different methods use different ranges and sometimes different units, which is why you compare your result only to the range on your own report, and why you should use the same lab when tracking a trend.
When a company overlays a narrower “optimal” or “functional” band on top of that range, it has added something the laboratory did not. Sometimes that reflects real literature. Sometimes it reflects a house opinion. You usually can’t tell from the dashboard, because the source is rarely cited.
Vitamin D makes the problem concrete. In April 2021, the U.S. Preventive Services Task Force reviewed screening for vitamin D deficiency in asymptomatic adults and issued an I statement, meaning the evidence was insufficient to weigh benefits against harms. The Task Force also noted that no single blood level defines deficiency, and that the trials it reviewed used cutoffs ranging from under 20 to under 31.2 nanograms per milliliter. It found that treating deficiency showed no benefit for all-cause mortality, fractures or new diabetes.
So when a dashboard tells you your vitamin D is suboptimal, it is applying a threshold that the national body charged with reviewing this evidence says is not settled. That’s not a conspiracy. It’s just a much weaker claim than the red bar implies.
When the company explaining your result also sells the fix
Here is the part that deserves a plain name.
If one company sells you the test, writes the paragraph that interprets your result, and then sells the supplement that paragraph recommends, every link in that chain has a financial reason to find something wrong with you. Nobody has to lie for that to shape the outcome. Choosing a narrow range instead of a wide one, flagging in yellow rather than green, writing “may indicate” instead of “is within the expected range for healthy adults,” all of it tilts in one direction when the next click is a shopping cart.
Does marketing for consumer tests overstate? There’s evidence it does. A 2023 content analysis in JAMA Network Open, led by Alexis Johnson, reviewed 27 websites across seven countries selling anti-Müllerian hormone tests directly to consumers. Twenty of them, about three quarters, stated the test indicated the likelihood of conceiving. Only nine, about a third, mentioned that it cannot accurately predict the chance of conception. The authors concluded that most sites carried false and misleading claims. That study covers one hormone test and isn’t US-only, so read it as a description of how this category markets itself rather than a verdict on any particular American company.
Federal advertising rules are relevant here, and most buyers have never heard of them. The Federal Trade Commission’s Health Products Compliance Guidance, published in December 2022, says health benefit claims need competent and reliable scientific evidence, which generally means randomized controlled human testing. Testimonials don’t substitute for that evidence. Anyone who participates in the marketing can be held responsible. And a material connection between an endorser and the advertiser, including payment or a paid position, has to be disclosed clearly and conspicuously.
Apply that last rule to the “practitioner” who reviewed your panel and recommended a product sold by the same company. That is a material connection. Ask whether it’s disclosed.
The downstream risk isn’t theoretical either. The NIH Office of Dietary Supplements points out that supplements don’t need FDA approval before they go on sale the way drugs do, and that risk climbs with high doses and with stacking many products at once. Real interactions exist: vitamin K can reduce how well warfarin works, and St. John’s wort speeds the breakdown of many medicines. A supplement regimen assembled from a dashboard is not a free action.
Galior and Baumann, in their 2020 review in Clinics in Laboratory Medicine, named result interpretation as one of the three core weak points of consumer testing, alongside collection errors and reporting. Interpretation is exactly the step these companies have filled, and exactly the step where their interests and yours can diverge.
What to ask before you order a panel
Run through these before you hand over a credit card. The first two usually end the discussion.
- What decision will I make differently depending on the result? If you can’t name one, you’re buying a number, not information.
- If this comes back flagged, who is going to help me figure out what it means, and have I asked them already?
- Which laboratory runs the sample, and is it CLIA-certified? The company’s name on the box is often not the lab’s name.
- Is the result reported with the laboratory’s own reference range and units, or only with the company’s interpretation? You want the raw report.
- Where did any “optimal” range come from, and can the company point to published evidence for it?
- Does the company sell products it recommends based on results? If so, is that relationship disclosed anywhere other than the fine print?
- What happens to my sample and my data afterward, and can I have both deleted?
- If something is seriously abnormal, does anyone call me, or does it just appear in a portal?
When a result needs a clinician, quickly
Most flagged values on a consumer panel are noise. A few are not, and the pattern that separates them is usually simple: an abnormal number plus a symptom.
If a panel flags low hemoglobin and you’ve also been unusually short of breath climbing stairs, that’s a call this week, not a supplement purchase. A flagged blood sugar alongside new thirst, frequent urination or unexplained weight loss is the same. A kidney or liver value well outside the range in someone who feels genuinely unwell is not a wait-and-see.
Severe bleeding, one-sided weakness, sudden confusion, trouble breathing or chest pain is an emergency no matter what the panel said. Call 911. The lab question can wait.
Two practical notes. Bring the actual laboratory report to the appointment, not a screenshot of the dashboard. A clinician needs the analyte name, the value, the units, the lab and the lab’s own reference range, and the marketing layer strips most of that out. And don’t start or stop any medication based on a consumer panel without talking to the person who prescribed it.
The FDA’s position on consumer tests generally is worth repeating verbatim, because it’s short: they “are not a substitute for a traditional health care evaluation.”
If you already bought a panel, do this
Save the raw report as a file, with the laboratory’s name and the collection date. That document is the thing with lasting value. The dashboard is not.
Pick out the one or two values that concern you and ignore the rest for now. Take those to a clinician as data to be interpreted, not as a diagnosis to be confirmed.
Before acting on any borderline value, repeat it at the same laboratory. A single number is a snapshot of one morning, and a surprising number of them look different the second time.
And carry the real lesson forward to the next ad you see. The useful question was never “what do all these numbers mean.” It was “what would I do differently if I knew.” Answer that first, and most of the panel stops being worth buying.
Sources
- Centers for Medicare & Medicaid Services. “Direct Access Testing (DAT) and CLIA.” cms.gov
- Centers for Medicare & Medicaid Services. “Clinical Laboratory Improvement Amendments (CLIA).” cms.gov
- U.S. Food and Drug Administration. “Clinical Laboratory Improvement Amendments (CLIA).” fda.gov
- U.S. Food and Drug Administration. “Direct-to-Consumer Tests.” fda.gov
- MedlinePlus, National Library of Medicine. “How to Understand Your Lab Results.” medlineplus.gov
- U.S. Preventive Services Task Force. “Vitamin D Deficiency in Adults: Screening.” uspreventiveservicestaskforce.org
- Federal Trade Commission. “Health Products Compliance Guidance.” ftc.gov
- NIH Office of Dietary Supplements. “Dietary Supplements: What You Need to Know.” ods.od.nih.gov
- PubMed. “Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. "General health checks in adults for reducing morbidity and mortality from disease." Cochrane Database of Systematic Reviews, 2019. DOI: 10.1002/14651858.CD009009.pub3.” doi.org
- PubMed. “Fiala C, Taher J, Diamandis EP. "Benefits and harms of wellness initiatives." Clinical Chemistry and Laboratory Medicine, 2019. DOI: 10.1515/cclm-2019-0122.” doi.org
- PubMed. “Johnson A, Thompson R, Nickel B, et al. "Websites Selling Direct-to-Consumer Anti-Mullerian Hormone Tests." JAMA Network Open, 2023. DOI: 10.1001/jamanetworkopen.2023.30192.” doi.org
- PubMed. “Galior KD, Baumann NA. "Challenges with At-home and Mail-in Direct-to-Consumer Testing: Preanalytical Error, Reporting Results, and Result Interpretation." Clinics in Laboratory Medicine, 2020. DOI: 10.1016/j.cll.2019.11.006.” doi.org